Inhibition by ginkgolides and bilobalide of the production of nitric oxide in macrophages (THP-1) but not in endothelial cells (HUVEC).
Nitric oxide (NO) is a principal mediator in many physiological and pathological processes. NO produced by constitutive nitric oxide synthase in endothelial cells (eNOS) acts as a vasodilator, whereas excess NO production due to elevated expression of inducible nitric oxide synthase (iNOS) may produce cytotoxic effects to cells in the vascular wall. We demonstrated in our previous work that the extract of Ginkgo biloba leaves (EGb) inhibits iNOS-mediated NO production. The objective of the present study was to investigate the effects of several active EGb components on iNOS-mediated NO production in macrophages derived from a human monocytic cell line (THP-1), as well as on eNOS-mediated NO production in human umbilical vein endothelial cells (HUVEC). Ginkgolide A, ginkgolide B, or bilobalide (0.25 to 1.0 microg/mL) caused a 30-65% reduction in the levels of NO metabolites released by THP-1 macrophages after 4 hr of incubation, with a corresponding decrease in iNOS activity. Western immunoblotting analysis coupled with a nuclease protection assay and reverse transcription-polymerase chain reaction revealed a concomitant reduction in the levels of iNOS protein mass and mRNA in ginkgolide A-, ginkgolide B-, or bilobalide-treated macrophages. On the other hand, these compounds did not affect eNOS-mediated NO production or the expression of eNOS protein and mRNA in HUVEC. Taken together, these results suggest that ginkgolide A, ginkgolide B, and bilobalide may contribute to the selective inhibitory effect of EGb on iNOS expression without affecting eNOS-mediated NO production.
Department of Pharmacology, Institute of Cardiovascular Science and Medicine, Faculty of Medicine, The University of Hong Kong, 1/F, Li Shu Fan Building, 5 Sassoon Road, Pokfulam, Hong Kong.
F
F
Cheung
Y L
YL
Siow
K
K
O
D002478:Cells, Cultured; D003517:Cyclopentanes / Q000494:pharmacology*; D004224:Diterpenes; D004347:Drug Interactions; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D016166:Free Radical Scavengers / Q000494:pharmacology; D005663:Furans / Q000494:pharmacology*; D015870:Gene Expression / Q000187:drug effects; D046934:Ginkgolides; D006801:Humans; D007328:Insulin / Q000031:analogs & derivatives*; D061268:Insulin Lispro; D007783:Lactones / Q000494:pharmacology*; D008264:Macrophages / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism*; D019001:Nitric Oxide Synthase / Q000096:biosynthesis / Q000187:drug effects / Q000235:genetics; D052247:Nitric Oxide Synthase Type II; D012333:RNA, Messenger / Q000096:biosynthesis / Q000187:drug effects
D003517:Cyclopentanes; D004224:Diterpenes; D016166:Free Radical Scavengers; D005663:Furans; D046934:Ginkgolides; D007328:Insulin; D061268:Insulin Lispro; D007783:Lactones; D012333:RNA, Messenger; D009569:Nitric Oxide; C045856:ginkgolide B; C496319:NOS2 protein, human; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C073710:bilobalide